| Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study D Kim, N Adeniji, N Latt, S Kumar, PP Bloom, ES Aby, P Perumalswami, ... Clinical Gastroenterology and Hepatology 19 (7), 1469-1479. e19, 2021 | 223 | 2021 |
| The in ovo chick chorioallantoic membrane (CAM) assay as an efficient xenograft model of hepatocellular carcinoma M Li, RR Pathak, E Lopez-Rivera, SL Friedman, JA Aguirre-Ghiso, ... Journal of visualized experiments: JoVE, 2015 | 92 | 2015 |
| Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitis M Li, D Wong, AS Vogel, JS Sack, OE Rahma, FS Hodi, SD Zucker, ... Hepatology 75 (3), 531-540, 2022 | 43 | 2022 |
| Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis M Li, JS Sack, OE Rahma, FS Hodi, SD Zucker, S Grover Cancer 126 (23), 5088-5097, 2020 | 38 | 2020 |
| A comparison of a large language model vs manual chart review for the extraction of data elements from the electronic health record J Ge, M Li, MB Delk, JC Lai Gastroenterology 166 (4), 707-709. e3, 2024 | 23 | 2024 |
| Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer M Li, JS Sack, P Bell, OE Rahma, A Srivastava, S Grover, SD Zucker JAMA oncology 7 (11), 1711-1714, 2021 | 23 | 2021 |
| Association between Atazanavir‐induced hyperbilirubinemia and cardiovascular disease in patients infected with HIV M Li, WW Chan, SD Zucker Journal of the American Heart Association 9 (19), e016310, 2020 | 18 | 2020 |
| Bleeding outcomes following transesophageal echocardiography in patients with cirrhosis and esophageal varices JS Sack, M Li, SD Zucker Hepatology communications 5 (2), 283-292, 2021 | 11 | 2021 |
| Early Liver Specialist Consultation is Associated with Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor–Induced Hepatitis M Li, D Wong, JS Sack, AS Vogel, FS Hodi, L Fong, JC Lai, S Grover, ... Journal of the National Comprehensive Cancer Network 21 (6), 617-626. e3, 2023 | 4 | 2023 |
| LIMITED UTILITY OF LIVER BIOPSY IN THE DIAGNOSIS AND MANAGEMENT OF HIGH-GRADE IMMUNE CHECKPOINT INHIBITOR HEPATITIS IN PATIENTS WITH ADVANCED MELANOMA M Li, JS Sack, OE Rahma, S Grover, SD Zucker The Liver Meeting Digital Experience™, 2020 | 2 | 2020 |
| Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients M Li, D Wong, JS Sack, AS Vogel, FS Hodi, L Fong, JC Lai, SD Zucker, ... Clinical Gastroenterology and Hepatology, 2024 | 1 | 2024 |
| Patient-focused drug development in primary sclerosing cholangitis: Insights on patient priorities and involvement in clinical trials M Li, RA Pai, R Gomel, M Vyas, SC Callif, J Hatchett, CL Bowlus, JC Lai Hepatology Communications 8 (6), e0433, 2024 | | 2024 |
| Mo1596 VALIDATING THE NEW PRIMARY SCLEROSING CHOLANGITIS ICD-10 CODE M Wang, M Dao, M Delk, C Fenton, JB Rubin, JC Lai, M Li Gastroenterology 166 (5), S-1708, 2024 | | 2024 |
| NETWORK ANALYSIS OF SYMPTOMS EXPERIENCED BY PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS M Wang, AM Shui, J Hatchett, RA Pai, R Gomel, MP Vyas, SC Callif, ... HEPATOLOGY 78, S2058-S2059, 2023 | | 2023 |
| A MULTICENTER STUDY OF THE DIAGNOSTIC AND PROGNOSTIC UTILITY OF AUTOANTIBODIES IN HIGH-GRADE IMMUNE CHECKPOINT INHIBITOR HEPATITIS M Li, A Vogel, JS Sack, L Fong, JC Lai, S Grover, SD Zucker HEPATOLOGY 78, S652-S652, 2023 | | 2023 |
| Caregiver‐reported symptom burden and preferences for therapeutic goals in pediatric primary sclerosing cholangitis HP Shifman, J Hatchett, RA Pai, R Safer, R Gomel, M Vyas, M Li, JC Lai, ... Journal of Pediatric Gastroenterology and Nutrition, 2023 | | 2023 |
| THE EXTERNALLY-LED PATIENT-FOCUSED DRUG DEVELOPMENT MEETING FOR PRIMARY SCLEROSING CHOLANGITIS: INSIGHTS ON PATIENT INVOLVEMENT IN CLINICAL TRIALS M Li, RA Pai, R Gomel, MP Vyas, SC Callif, J Hatchett, R Safer, ... HEPATOLOGY 78, S2079-S2080, 2023 | | 2023 |
| PREDICTING STEROID-REFRACTORY IMMUNE CHECKPOINT INHIBITOR HEPATITIS: DEVELOPMENT AND EXTERNAL VALIDATION OF THE NOVEL SUNLIT MODEL AND IDENTIFYING A CUTOFF FOR BIOCHEMICAL … M Li, JS Sack, A Vogel, L Fong, SD Zucker, S Grover, JC Lai HEPATOLOGY 78, S658-S659, 2023 | | 2023 |
| Aldosterone Antagonist Dosing and the Risk of Hyponatremia in Patients With Cirrhosis and Ascites AS Vogel, M Li, SD Zucker Gastro Hep Advances 2 (1), 2-4, 2023 | | 2023 |
| THE RISK OF PERITONITIS FROM TUNNELED PERITONEAL CATHETERS IS NOT INCREASED IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSIVE ASCITES MJ Senter-Zapata, T Barlowe, M Manning, M Li, SD Zucker, JS Sack HEPATOLOGY 76, S1191-S1192, 2022 | | 2022 |
